¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£ÇÐȸ The Liver Week 2019 DAY 2 : 2019-06-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°£ÇÐȸ The Liver Week 2019 DAY 2 : 2019-06-21
±³À°ÀÏÀÚ : 2019-06-21
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ ROOM A [1F] 103-105 / 108-110, ROOM B [1F] 101, ROOM C [1F] 102, ROOM BC [1F] 101-102, ROOM D [1F] 106, ROOM E [1F] 107, ROOM A [2F] 201-202, ROOM B [2F] 203, ROOM D [2F] 205  
±³À°ÁÖÁ¦ : The Liver Week 2019 DAY 2
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051  
À̸ÞÀÏ : kasl@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 23 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í »çÀüµî·Ï: ȸ¿ø 140000/ÀüÀÓ 80000/ºñȸ¿ø 170000 ÇöÀåµî·Ï: ȸ¿ø 150000/ÀüÀÓ 100000/ºñȸ¿ø 200000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 08:30~08:50 Fecal Microbiota Transplant in Alcohol-Related Liver Diseases  SM Shasthry(Institute of Liver and Biliary Sciences, India) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 08:50~09:10 Systemic Manifestation in Non-Alcoholic Fatty Liver Disease  Donghee Kim(Stanford Univ., USA) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 09:10~09:30 Update on the Management of Non-Alcoholic Fatty Liver Disease  Vincent Wong(The Chinese Univ. of Hong Kong, Hong Kong) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:10~11:25 Nucleoside Analogue NUC) Treatment Can Be Discontinued  Chun-Jen Liu(National Taiwan Univ., Taiwan) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:25~11:40 NUC Treatment Should Be Continued  Young-Suk Lim(Univ. of Ulsan) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:40~12:10 Panel Discussion  Hyung Joon Yim, Wai-Kay Seto(Korea Univ. , Univ. of Hong Kong, Hong Kong) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 13:30~14:00 Hepatitis B Virus: From Control to Cure  Jia-Horng Kao(Taiwan National Univ., Taiwan) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:00~14:20 Viral factors for Hepatitis B Virus-Related Hepatocellular Carcinoma  Jeong Won Jang(The Catholic Univ. of Korea) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:20~14:40 Novel Biomarkers in Management of Chronic Hepatitis B  Yasuhito Tanaka(Nagoya City Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:40~15:00 Current Treatment Strategy: Toward Hepatitis B Virus Cure  Seng Gee Lim(National Univ. of Singapore, Singapore) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 15:00~15:20 Future Treatment Strategy: Toward Hepatitis B Virus Cure  Henry LY Chan(The Chinese Univ. of Hong Kong, Hong Kong) 
Åä·Ð 06-21 ROOM A [1F] 103-105 / 108-110 15:20~15:30 Discussion  () 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 16:30~16:50 Chronic Hepatitis B: Where Are We Now for Functional Cure?  Hyun Woong Lee(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 16:50~17:10 Non-Alcoholic Steatohepatitis: Key Targets and Endpoints  Byoung Kuk Jang(Keimyung Univ.) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 17:10~17:30 Cirrhosis: Effort against Fibrosis and Portal Hypertension  Kyung-Ah Kim(Inje Univ.) 
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 17:30~17:50 Hepatocellular Carcinoma Treatment Showdown: Mono vs. Combination Therapy  Ju Hyun Shim(Univ. of Ulsan) 
±³À°½Ã°£ 06-21 ROOM B [1F] 101 07:30~07:55 Management of Cirrhotic Complications: Guidelines and Real Experience  C. Rinaldi A. Lesmana(Univ. of Indonesia, Indonesia) 
±³À°½Ã°£ 06-21 ROOM B [1F] 101 07:55~08:20 Key Summary of EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis  Paolo Angeli(Univ. of Padova, Italy) 
Åä·Ð 06-21 ROOM B [1F] 101 08:20~08:30 Discussion  () 
±³À°½Ã°£ 06-21 ROOM C [1F] 102 07:30~07:50 Recent Epidemiology of Non-Alcoholic Fatty Liver Disease  Donghee Kim(Stanford Univ., USA) 
±³À°½Ã°£ 06-21 ROOM C [1F] 102 07:50~08:10 Non-Alcoholic Fatty Liver Disease and Diabetes: Chicken or Egg?  Eun-Jung Rhee(Sungkyunkwan Univ.) 
Åä·Ð 06-21 ROOM C [1F] 102 08:10~08:30 Discussion  () 
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:10~11:25 Treatment of Chronic Hepatitis B and C  Eileen L. Yoon(Inje Univ.) 
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:25~11:40 Management of Acute Variceal Bleeding  Seung Kak Shin(Gachon Univ.) 
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:40~11:55 Liver Transplantation: When and How?  Bum Soo Kim(Kyung Hee Univ.) 
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:55~12:10 Hepatocellular Carcinoma: Diagnosis and Tumor Staging  Woo Jin Chung(Keimyung Univ.) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:10~11:25 Exceptional Insurances in the Field of End-Stage Liver Disease  Jeong Han Kim(Konkuk Univ.) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:25~11:40 Policy of KASL for Elimination of Hepatitis  Sung Eun Kim(Hallym Univ.) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:40~11:55 Liver Disease-Related Issue to Strengthen Health Insurance Coverage Expansion Policy  Eun Sun Jang(Seoul National Univ.) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:55~12:10 Future Policy of Government for Administration of Chronic Liver Disease  Young Ki Jeong(Ministry of Health and Welfare) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:00~14:20 Overview of Hepatitis Prevention and Control in the Republic of Korea  Sung Won Lee(The Catholic Univ. of Korea) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:20~14:40 National Viral Hepatitis Control Plan  Don Han Lee(Korea Centers for Disease Control and Prevention) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:40~14:55 Korea HBV Cohort Study  Beom Kyung Kim(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:55~15:10 Korea HCV Cohort Study  Eun Sun Jang(Seoul National Univ.) 
Åä·Ð 06-21 ROOM D [1F] 106 15:10~15:30 Discussion  () 
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:00~14:20 Comparison of Bone Marrow-derived Mesenchymal Stem Cells Isolated from Normal and Cirrhotic Patients  Young Woo Eom(Yonsei Univ. Wonju) 
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:20~14:40 Feasibility of Enhanced PRL-1 in Placenta-derived Mesenchymal Stem Cells by Gene Modification on a Rat Model with Hepatic Failure  Gi Jin Kim(CHA Univ.) 
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:40~15:00 Vascularized Liver Tissue with Different Types of Endothelial Cells and Recovery Aids for Acute Liver Failure  Soo Hyun Kim(KIST) 
±³À°½Ã°£ 06-21 ROOM E [1F] 107 15:00~15:20 MicroRNA Profile Analysis in Liver Fibrotic Tissue and Hepatic Differentiated Human Bone Marrow-derived Mesenchymal Stem Cells  Jung Hoon Cha(The Catholic Univ. of Korea) 
±³À°½Ã°£ 06-21 ROOM E [1F] 107 15:20~15:40 Proteomics Approach for Translational Research, Focusing on Liver Disease  Kyung Kon Kim(Univ. of Ulsan) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 08:30~09:00 Updated Liver Allograft Pathology  Chris Bellamy(The Univ. of Edinburgh, Scotland) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 09:00~09:30 Is it Need Protocol Biopsy in Liver Recipient?  Suk Kyun Hong(Seoul National Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:10~11:25 Pathological Point of View of Combined HCC and CCC: What Is the Origin and Diagnostic Criteria of Combined HCC and CCC  Young Nyun Park(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:25~11:40 Imaging Features of Combined HCC and CCC: What Is the Difference Compared with HCC or CCC?  Chang-Hee Lee(Korea Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:40~11:55 Surgical Treatment and Prognosis of Combined HCC and CCC  Matsuyama Ryusei(Yokohama City Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:55~12:10 Issues of Combined HCC and CCC in Liver Transplantation  Young Seok Han(Kyungpook National Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 13:30~14:00 Donation after Circulatory Death Liver Procurement in Real Practice  Koji Hashimoto(Cleveland Clinic, USA) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:10~14:30 Current Status and Problems of Organ Donation  Won Hyun Cho(Korea Organ Donation Agency) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:30~14:50 Current Status of Liver Allocation System  Jae Geun Lee(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:50~15:10 Institutional Issue and Limit of Donation after Cardiac Death  Dong-Sik Kim(Korea Univ.) 
Åä·Ð 06-21 ROOM A [2F] 201-202 15:10~15:30 Panel Discussion  Jeong-Rim Lee(Korea Organ Donation Agency, TBD) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 16:30~16:50 HRS: Definition, Pathophysiology and Medical Management  Yeon Seok Seo(Korea Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 16:50~17:10 When to Consider SLK and How to Prevent Adverse Renal Outcome after Liver Transplantation  Jae Min Chun(Kyungpook National Univ.) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 17:10~17:30 MELD Purgatory in HRS and Allocation Policy: When to Start Renal Replacement Therapy?  Shin Hwang(Univ. of Ulsan) 
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 17:30~17:50 Optimal Time to Start Renal Replacement Therapy: Nephrologist  Hye Ryoun Jang(Sungkyunkwan Univ.) 
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:10~14:30 Recovery Management for Old Age Recipient  Man Ki Ju(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:30~14:50 Transplantation Counseling for old Age Recipient  Hyung Sook Kim(Seoul St. Mary) 
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:50~15:10 Acute Liver Failure  Dong Jin Joo(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM B [2F] 203 15:10~15:30 Patient Management after Liver Transplantation  Seung Heui Hong(Samsung Medical Center) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 08:30~08:50 Surveillances for HCC in Patients with NAFLD  Vincent Wong(The Chinese Univ. of Hong Kong, Hong Kong) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 08:50~09:10 Are Emerging Biomarkers and Imaging Tools Better than Routine Abdominal Sonography for HCC Surveillance?  Do Young Kim(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 09:10~09:30 Is LI-RADS Better for Diagnosis of HCC  Jeong Min Lee(Seoul National Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 11:10~11:25 0202 Liver Day Special Lecture  Hyun Woong Lee(Yonsei Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 13:30~13:50 Circulating Tumor Cells and Cell-Free Nucleic Acids  Takahiiro Ochiai(Tokyo Medical Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 13:50~14:10 CAR-Associated Adoptive Immunotherapy  Yutaka Kawakami(Keio Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:10~14:30 Oncolytic Virus-Based Therapy for HCC  Jeong Heo(Pusan National Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:30~14:45 Recent Trends of Treatment for Intermediate Stage HCC: Japanese Experience  Masatoshi Kudo(Kindai Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:45~15:00 Recent Trends of Treatment for Intermediate Stage HCC: Korean Experience  Ji Hoon Kim(Korea Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 15:00~15:15 Recent Trends of Treatment for Advanced Stage HCC: Japanese Experience  Kazuomi Ueshima(Kindai Univ., Japan) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 15:15~15:30 Recent Trends of Treatment for Advanced Stage HCC: Korean Experience  Won Young Tak(Kyungpook National Univ.) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 16:30~16:50 First Line Treatments for HCC  Arndt Vogel(Hannover Medical School, Germany) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 16:50~17:10 Second Line Treatments for HCC  Anthony El-Khoueiry(Univ. of Southern California Norris Comprehensive Cancer Center, USA) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 17:10~17:30 A Future of Systemic Agents: Emerging Therapies and Strategies  Baek-Yeol Ryoo(Univ. of Ulsan) 
±³À°½Ã°£ 06-21 ROOM D [2F] 205 17:30~17:50 Combination of Interventional and Systemic Therapies: Current Status and Future Direction  Joong-Won Park(National Cancer Center Korea) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£ÇÐȸ The Liver Week 2019 DAY 2 : 2019-06-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ ½ÉÆ÷Áö¿ò / ¿öÅ©¼¥ : 2019-06-21
´ÙÀ½±Û [Á¦28±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] ¸®´õ·Î¼­ÀÇ ´ö¸ñ : 2019-06-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 7 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 12 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 4 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 4 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 7 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 7 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 2 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 1 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 2 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 3 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 1 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 2 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 5 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷